Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy
NCT07587814
·
clinicaltrials.gov ↗
NA
Phase
NOT_YET_RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Carcinoma
Castration Resistant Prostatic Neoplasms
Interventions
RADIATION:
177Lu-PSMA-617 + SPECT/CT dosimetry
Sponsor
Centre Henri Becquerel